(1 - 13 von 30
)
Santhera im Geschäftsjahr mit Einnahmen von CHF 20,6 Mil ...
www.mittelstandcafe.de
Klaus Schollmeier, Chief Executive Officer von Santhera. «Ein weiterer wichtiger. Höhepunkt des vergangenen Jahres war die Auslizenzierung von Fipamezole an Ipsen für Regionen ausserhalb Nordamerikas und Japans. ...
Biovail to acquire Santhera's US & Canadian rights of JP
test.pharmabiz.com
... will become a key product for the improved management of Parkinson's disease," said Klaus Schollmeier, chief executive officer of Santhera." › news
Inthera Bioscience AG Expands Management Team with Seasoned...
www.b3cnewswire.com
Inthera Bioscience announced that Bernd Hentsch joins the company as Chief Development Officer, Ralph Lindemann as CSO and Monique Schiersing as COO.
Baxter Acquires SuppreMol - Contract Pharma
www.contractpharma.com
— ... goal to treat important autoimmune diseases and severe allergies,” said Klaus Schollmeier, Ph.D., chief executive officer of SuppreMol. › ...
sortiert nach Relevanz / Datum